Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
trial crawled date : 2021 - 12 - 06 save search
Merck Announces Pause in Enrollment for Two Phase 3 Clinical Trials of Investigational, Once-Monthly, Oral Islatravir for Pre-Exposure Prophylaxis (PrEP) of HIV-1 infection
Published: 2021-12-06 (Crawled : 23:00) - biospace.com/
MRK | News | $125.78 0.44% 0.0% 8.4M
|
Health Technology
|
| O: 0.0%
H: 0.0%
C: 0.0%
trials trial clinical trials infection phase 3 hiv enroll infections
Acadia Pharmaceuticals Announces Positive Top-line Results from the Pivotal Phase 3 Lavender Trial of Trofinetide in Rett Syndrome
Published: 2021-12-06 (Crawled : 22:00) - biospace.com/
ACAD | $16.82 -1.47% -1.49% 3.5M
|
Health Technology
|
| O: -0.77%
H: 0.0%
C: 0.0%
trial positive results phase 3 syndros topline rett syndrome
Ventyx Biosciences Announces First Patient Dosed in a Phase 2 Clinical Trial of VTX002 for the Treatment of Moderate-to-Severe Ulcerative Colitis
Published: 2021-12-06 (Crawled : 22:00) - biospace.com/
VTYX | News | $4.47 2.76% 2.68% 910K
|
Manufacturing
|
| O: -1.39%
H: 0.0%
C: 0.0%
treatment phase 2 trial bioscience ulcerative colitis
IO Biotech Announces Third Clinical Collaboration with Merck to Evaluate IO102-IO103 in Combination With KEYTRUDA® (pembrolizumab) as First-Line Treatment in a Phase 2 Multi-Arm Basket Trial
Published: 2021-12-06 (Crawled : 22:00) - biospace.com/
IOBT | $1.47 0.0% 92K
|
|
| O: -5.23%
H: 0.0%
C: 0.0%
treatment phase 2 trial keytruda collaboration biotech iot
Industrial Degreaser Market Size by Revenue to Reach USD 24.3 Billion by 2026 - Arizton
Published: 2021-12-06 (Crawled : 22:00) - prnewswire.com
SCL | $84.17 2.57% 0.0% 69K
|
Process Industries
|
| O: 4.04%
H: 0.0%
C: -2.36%
trial
Trials Show Hope on the Horizon for Dravet Syndrome, Glioblastoma
Published: 2021-12-06 (Crawled : 19:00) - biospace.com/
KZIA | $0.379 9.47% 8.65% 300K
|
Health Technology
|
| O: -16.26%
H: 0.0%
C: 0.0%
trials trial syndros glioblastoma dravet syndrome
PDS Biotech Provides Recruitment update for National Cancer Institute-Led Phase 2 Clinical Trial of PDS0101-Based CombinationInstitutional Review Board (IRB) approval has been obtained and clinical trial recruitment resumes
Published: 2021-12-06 (Crawled : 15:30) - biospace.com/
PDSB | $2.64 -8.97% -9.85% 880K
|
Health Technology
|
| O: -2.14%
H: 0.0%
C: 0.0%
phase 2 trial approval cancer biotech iot
Upadacitinib (RINVOQ®) Achieved Primary and Key Secondary Endpoints in First Phase 3 Induction Study in Patients with Crohn's Disease
Published: 2021-12-06 (Crawled : 15:30) - biospace.com/
ABBV | $166.41 1.06% 0.0% 5.5M
|
Health Technology
|
| O: 1.57%
H: 0.0%
C: 0.0%
disease phase 3
Fulcrum Therapeutics® Announces Additional HBG mRNA Induction from Higher Dose Cohorts in Phase 1 Healthy Adult Volunteer Trial of FTX-6058 for Sickle Cell Disease and New Preclinical Mechanism Data
Published: 2021-12-06 (Crawled : 15:00) - biospace.com/
FULC | $6.86 -2.83% -2.92% 560K
|
Health Technology
|
| O: -0.78%
H: 0.0%
C: 0.0%
trial therapeutics disease preclinical phase 1 pre-clinical
MediWound Completes Enrollment of its EscharEx U.S. Phase 2 Adaptive Design StudyTopline Data Expected in the First Quarter of 2022
Published: 2021-12-06 (Crawled : 15:00) - biospace.com/
MDWD | $15.9 -6.42% -6.86% 110K
|
Health Technology
|
| O: -2.48%
H: 0.0%
C: 0.0%
phase 2 topline enroll designation
End Suction Pump Market to Exceed US$ 6.08 by 2031 with Industrial Sector Contributing 3/4th of Overall Sales: FMI
Published: 2021-12-06 (Crawled : 14:30) - prnewswire.com
XYL | $127.84 0.53% 0.0% 2.2M
|
Producer Manufacturing
|
| O: 1.39%
H: 0.0%
C: 0.0%
FLS | $45.8 0.37% 0.0% 670K
|
Producer Manufacturing
|
| O: 1.45%
H: 0.0%
C: 0.0%
sales trial
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages ReneSola Ltd. (SOL) Investors to Contact Firm's Attorneys, Firm Investigating Possible Securities Law Violations
Published: 2021-12-06 (Crawled : 14:30) - prnewswire.com
SOL | News | $1.7 -2.3% 0.0% 340K
|
Electronic Technology
|
| O: -11.48%
H: 0.0%
C: 0.0%
DOCU | $55.66 -2.42% -2.48% 2.2M
|
Technology Services
|
| O: 0.41%
H: 0.0%
C: 0.0%
trial
NCI-Sponsored Trial of Uproleselan in Older, Newly Diagnosed AML Patients Fit for Intensive Chemotherapy Completes Enrollment of Phase 2 Portion Ahead of Schedule
Published: 2021-12-06 (Crawled : 14:30) - biospace.com/
GLYC | $1.93 -10.65% -11.92% 1.2M
|
Health Technology
|
| O: 0.0%
H: 0.0%
C: 0.0%
phase 2 trial therapy enroll order aml
SCYNEXIS Announces Agreement with FDA on Innovative Strategy for Approval of Oral Ibrexafungerp for Treatment of Invasive Candidiasis
Published: 2021-12-06 (Crawled : 14:30) - biospace.com/
SCYX | $1.44 2.49% 2.43% 130K
|
Health Technology
|
| O: -0.92%
H: 0.0%
C: 0.0%
treatment fda approval
Catalyst Pharmaceuticals Announces DyDo Pharma Initiation of a Phase 3 Study for FIRDAPSE® (amifampridine) in Japan
Published: 2021-12-06 (Crawled : 14:30) - biospace.com/
CPRX | $15.12 -1.43% -1.46% 7.4M
|
Health Technology
|
| O: 1.38%
H: 0.0%
C: 0.0%
phase 3 pharma
NRx Announces Completion of Data Safety Meeting for Phase 2 Trial of BriLife Vaccine, Phase 2b/3 Registration Trial to Begin in Nation of Georgia, Israel, European Union, and Other Regions
Published: 2021-12-06 (Crawled : 14:30) - globenewswire.com
NRXP 2 d | $3.08 1.99% 1.95% 230K
|
Manufacturing
|
| O: -1.09%
H: 0.0%
C: 0.0%
israel phase 2 europe phase 2b trial vaccine brilife
Jaguar Health to Host Scientific Discussion about Cancer Therapy-Related Diarrhea in Breast Cancer and the Company’s Ongoing OnTarget Pivotal Phase 3 Trial at San Antonio Breast Cancer Symposium (SABCS 2021)
Published: 2021-12-06 (Crawled : 14:00) - biospace.com/
JAGX | $0.158 -10.79% -12.09% 30M
|
Health Technology
|
| O: -5.69%
H: 0.0%
C: 0.0%
ongoing trial diarrhea therapy cancer phase 3 breast cancer symposium
Bellicum Announces Positive Interim Data from Phase 1/2 GoCAR-T® Studies, Secures $35 Million Private Placement Equity Financing Priced at Market
Published: 2021-12-06 (Crawled : 14:00) - biospace.com/
BLCM | $0.0748 381.28% 6.1K
|
Health Technology
|
| O: -3.01%
H: 5.59%
C: -0.62%
car-t phase 1 positive
Cyclo Therapeutics Receives IND Clearance from the U.S. FDA to Advance its Phase 2 Study of Trappsol® Cyclo™ for the Treatment of Alzheimer’s Disease
Published: 2021-12-06 (Crawled : 14:00) - biospace.com/
CYTH | $1.19 -0.83% -0.84% 57K
|
Professional, Scientific, and T...
|
| O: 1.23%
H: 0.0%
C: 0.0%
alzheimer treatment fda phase 2 clearance therapeutics disease alzheimer’s alzheimer's disease alzheimer's
Acurx Announces First Patient Enrolled in Phase 2b Clinical Trial of its Lead Antibiotic for Treatment of Clostridioides difficile Infection (CDI)
Published: 2021-12-06 (Crawled : 14:00) - biospace.com/
ACXP | $2.02 -5.16% -5.45% 94K
|
Professional, Scientific, and T...
|
| O: 2.41%
H: 4.47%
C: 2.82%
treatment phase 2 phase 2b trial infection iot enroll infections
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
GBR | $1.42 31.48% 11.27% 990K
|
Energy Minerals
KUKE | $2.88 2.49% 7.64% 360K
|
MPLN | $0.6502 -11.74% 4.51% 2.2M
|
Finance
CXM 4 | $11.34 -0.44% 4.27% 1.7M
|
Information
PVL 4 | $1.47 -0.68% 4.08% 77K
|
Energy Minerals
RNR 4 | $224.74 0.85% 3.52% 310K
|
Finance
PZG | $0.4431 0.48% 2.91% 150K
|
Non-Energy Minerals
LEV | $0.972 0.73% 2.88% 570K
|
Manufacturing
DBRG | $17.3 0.06% 1.97% 1.2M
|
Finance and Insurance
OSK 4 | $117.72 0.05% 1.96% 370K
|
Producer Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.